Singapore: Buchang Pharma is likely to significantly increase its stake in the Tianyin-Buchang Alliance joint venture, totalling to a registered capital of joint venture of $33 million.

Tianyin Pharmaceutical's wholly owned subsidiary Chengdu Tianyin Pharmaceutical owns 95 percent and Buchang Pharma owns 5 percent.

Tiyanyin and Buchang Pharmaceutical in early 2015 established Tianyin-Buchang strategic alliance to synergize and accelerate the growth of the company, boosting the mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).